Dec 09, 2013
Pfizer Inc. has entered into an agreement with GSK to explore the anti-cancer efficacy and the safety of GSK's trametinib combined with Pfizer's palbociclib (PD-0332991) in a Phase I/II study in patients with advanced/metastatic melanoma.
Nov 19, 2013
A study published in the journal Nature Medicine suggests a potential new treatment for the seizures that often plague children with genetic metabolic disorders and individuals undergoing liver failure.
Nov 11, 2013
The most frequently mutated gene across all types of cancers is a gene called p53. Unfortunately it has been difficult to directly target this gene with drugs. Now a multi-institutional research team has identified a family of enzymes.
Nov 04, 2013
The Bayer Group continued its positive business momentum in the third quarter of 2013, with substantial contributions from the Life Science businesses HealthCare and CropScience
Nov 01, 2013
A team of 22 scientists from 11 research institutes led by Professor Bazbek Davletov, now at the University of Sheffield, created and characterised a new molecule that was able to alleviate hypersensitivity to inflammatory pain.
Oct 31, 2013
Pfizer Inc. reported financial results for third-quarter 2013. Reported revenues decreased $310 million, or 2%, which reflects an operational decline of $38 million, or less than 1%, and the unfavorable impact of foreign exchange of $272 m
Oct 30, 2013
An international team led by University of Adelaide researchers has identified the mechanism of pain relief of a new drug for treating Irritable Bowel Syndrome with Constipation (IBS-C)
Oct 29, 2013
A new review suggests that omega-3 fatty acids taken in excess could have unintended health consequences in certain situations, and that dietary standards based on the best available evidence need to be established.
Oct 28, 2013
University of Miami Miller School of Medicine researchers played a key role in the largest international Alzheimer's disease genetics collaboration, which identified 11 new regions of the genome that contribute to late-onset Alzheimer's disease.
Oct 25, 2013
Bristol-Myers Squibb Company (NYSE:BMY) has reported results for the third quarter of 2013 highlighted by the strong performance of key marketed products such as Yervoy, Orencia and Sprycel.